TWI823475B - USE OF ZnO/NSP COMPOSITE IN SKIN PROTECTION - Google Patents

Abstract

The present invention provides a skin protecting composition, comprising a zinc oxide-on-silicate platelet composite (ZnO/NSP composite). The ZnO/NSP composite is made of silicate platelet and ZnO particles adsorbed thereon, in which the ZnO particles are created by the dehydration of Zn(OH)₂ formed on the silicate platelet. The ZnO particles adhering on the silicate platelet can effectively improve the dispersibility of zinc oxide particles, and the average particle size can reach near nanometer size; moreover, exhibit better anti-bacterial and light-absorbing properties than ZnO itself, and are not toxic or irritating to the skin. The ZnO/NSP composite can be used in the preparation of skin-protecting compositions, especially cosmetic compositions.

Description

Use of Silicon Chip-Zinc Oxide Complex in Skin Protective Compositions

The present invention relates to the use of a silicon flake-zinc oxide composite (ZnO/NSP composite) for skin protection, and in particular to the use of a silicon flake-zinc oxide composite for preparing cosmetic compositions for skin protection.

Zinc oxide is known to be a physical sun blocker. Its absorption spectrum covers the band from 290 to 380nm, so it can protect all bands of UVB and UVA. The principle of physical sunscreen is to use opaque particles such as minerals in the product to directly block sunlight when it is exposed to such substances. However, due to the poor dispersion of commercially available zinc oxide, the usage amount is high, resulting in irritation during application. Unnatural shortcomings such as thickness and paleness are not easy to please the consumer public. Zinc oxide has also been used to treat and prevent diaper rash and other minor skin problems such as burns, cuts or scratches. It works by forming a barrier on the skin to keep out irritants or moisture.

In recent years, there have been many sunscreen products using zinc oxide nanoparticles. Although they can solve the problem of discomfort for consumers when applying, the safety of nanoparticles used in sunscreens has always been a controversial issue because of previous animal Exposure studies found that when nanoscale zinc oxide (ZnO) sunscreen was applied to the skin, skin absorption was much higher from human studies. And some public advocacy groups are concerned that sunscreens containing zinc oxide (ZnO) nanoparticles can penetrate into the upper layers of the skin and may to enter living cells in the living epidermis and cause toxicity, including DNA damage.

The present invention first discovered that the silicon wafer-zinc oxide composite made by forming zinc oxide on the surface of the silicon wafer can make the formed zinc oxide particles evenly dispersed and adsorbed on the surface of the silicon wafer, which can not only improve the market The disadvantage of zinc oxide is that it is not easily dispersed, and it is not toxic or irritating to human skin. At the same time, it can improve the properties of zinc oxide and effectively reduce the usage of zinc oxide.

Accordingly, one aspect of the present invention relates to the use of a ZnO-on-silicate platelet composite for preparing a skin protection composition.

In some specific embodiments of the present invention, the composition is a cosmetic composition, preferably a skin protective cream, lotion or skin care cleansing product, including sunscreen cream, shampoo/milk, and hair lotion. tonic) and so on.

In another aspect, the present invention relates to a cosmetic composition for skin protection, comprising a silicon flake-zinc oxide complex and a carrier, excipient or diluent.

In some embodiments of the present invention, the composition is a sunscreen lotion, or antibacterial shampoo/milk or hair tonic.

Figure 1 is an SEM observation photo of the appearance of the silicon wafer-zinc oxide composite of the present invention. The length of the marked horizontal line represents 2 μm. The red circle in the figure is the area where ZnO is pulled out for energy dispersion X-ray spectroscopy (EDS).

Figure 2A shows the results of TEM observation after the silicon wafer-zinc oxide composite powder of the present invention is dispersed. The length of the marked horizontal line represents 100 nm. Figure 2B is a spectrum of X-ray diffraction analysis of the silicon wafer-zinc oxide composite in powder form. The red line is the standard spectrum of ZnO.

Figure 3 shows the toxicity evaluation results of the silicon chip-zinc oxide complex of the present invention to skin cells: human epidermal cells HaCaT (A), human skin fibroblasts Hs68 (B) and mouse melanocytes B16F10 (C). After the cells were co-cultured with zinc oxide-silica complex solutions at different concentrations (0, 1, 10, 100, 500, 1000, 5000ppm) for 24 hours, MTT analysis was performed to determine whether the cells were treated with zinc oxide-silica complex. The survival rate after treatment (expressed as a percentage relative to the survival rate of the untreated control group).

Figure 4 is a 3D transdermal absorption test of the silicon wafer-zinc oxide composite of the present invention, and the observation results of the epidermal tissue under a microscope at 400X magnification. 16% (equivalent to 1.6x10 ⁵ ppm) silicon flake-zinc oxide complex suspension was applied to the skin. After 6 hours (A) and 24 hours (B) of transdermal absorption experiments, the epidermis was observed with a microscope. Distribution of ZnO/NSP particles in tissues. The circles in the figure indicate the positions of ZnO/NSP particles in each skin layer.

Figure 5 is a comparison result of the full spectrum scan (200~600nm) of the silicon wafer-zinc oxide composite of the present invention and commercially available zinc oxide. The maximum absorption of the silicon wafer-zinc oxide composite appears at 367 nm, while the maximum absorption of commercially available zinc oxide appears at 375 nm, and the silicon wafer-zinc oxide composite of the present invention exhibits stronger UV absorption.

Figure 6 shows Malassezia globosa using (A) the silicon wafer-zinc oxide complex liquid of the present invention at a concentration of 0.1% (prepared in the culture medium in powder form), and (B) the concentration of 1%. The test results of the antibacterial concentration of the invented silicon wafer-zinc oxide complex liquid (prepared in liquid form in the culture medium).

The "silica flakes" described in the present invention are an independent flake structure (also known as natural silicon flakes, NSP) obtained by complete delamination of natural layered clay. The main component is hydrated and water-dispersible silicon aluminum oxide. (SiO ₂ ‧Al ₂ O ₃ ‧xH ₂ O), its cation exchange equivalent (CEC) is about 80-200mequiv/100g. The preparation method of silicon wafers has been seen in many documents (for example, US 6,765,050 B2), which mainly includes placing natural clay such as montmorillonite (montmorillonite), deionized water (deionized water), surfactants and other raw materials into a reaction After heating and continuous stirring in the tank until the delamination and dispersion reactions are completed, a modified montmorillonite product (gray jelly) is obtained, which is called "silica flakes".

Example 1. Preparation and analysis of physical and chemical properties of silicon wafer-zinc oxide composite

The manufacturing method of the silicon wafer-zinc oxide composite of the present invention mainly includes: adding an aqueous solution of zinc salt into the silicon wafer suspension to perform a metal ion exchange reaction; adding NaOH to form zinc hydroxide on the surface of the silicon wafer; Zinc hydroxide is dehydrated at 99°C to form zinc oxide particles, which are adsorbed on the surface of silicon wafers to obtain a liquid silicon wafer-zinc oxide composite; the liquid silicon wafer-zinc oxide composite is then filtered, dried and ground to obtain Powdered silicon flake-zinc oxide composite.

A manufacturing example is provided below. Weigh the silicon wafer (0.85g) and place it in a three-neck round-bottom flask, add ddH ₂ O to bring the total weight to about 26g, and stir at 80°C for 30 minutes to homogenize. , forming a silicon chip suspension. Zinc acetate solution (41 g, 1% w/w) was added to the three-neck round bottom flask, and approximately 5 mL of ddH ₂ O was added for cleaning. Place at 80°C and stir at 500 rpm for 30 minutes. Sodium hydroxide solution (22g, 1% w/w) was added to the three-neck round-bottom flask, and approximately 5 mL of ddH2O was added for cleaning. The mixture was reacted at 80° C. at a rotation speed of 500 rpm for 1 hour, and then cooled at room temperature. After cooling to room temperature, a liquid silicon wafer-zinc oxide composite is obtained. The product was filtered using suction. The filter cake is collected and dried at 120°C until the moisture content is less than 5%. Finally, the dried product is ground to obtain a powdered silicon flake-zinc oxide composite.

Under SEM (HITACHI SU-5000) observation, the ZnO particles adsorbed on the silicon wafer will aggregate with each other and present a 3D spherical structure. Under SEM, it can be seen that the entire wafer is full of ZnO, while the silicon wafer is Covered underneath. Combined with laser scattering data, it also shows that ZnO particles can become larger 3D aggregates after stacking (Figure 1).

)計算ZnO顆粒的平均粒徑，算得每個ZnO本身的粒子大小係介於15~20nm，約為17nm左右(以primary structure原始晶格計算，ZnO具有良好晶格)。 In order to further examine the individual particles and stacking patterns of ZnO, the obtained powdered silicon flake-zinc oxide composite was dispersed and observed with a transmission electron microscope (TEM, JEOL JEM-3010). As shown in Figure 2A, the silicon wafer unfolds in 2D, with dispersed ZnO particles attached to its surface. The particle size distribution of the silicon wafer-zinc oxide composite mainly falls in the range of 1.0 μm to 20.0 μm. Then, the powdered silicon wafer-zinc oxide composite was subjected to X-ray diffraction analysis (X-ray Diffraction). The results are shown in Figure 2B. Use the Scherrer equation(

) Calculate the average particle size of ZnO particles and find that the particle size of each ZnO itself is between 15 and 20nm, about 17nm (calculated based on the original lattice of the primary structure, ZnO has a good lattice).

Settlement analysis. Use RO water to prepare ZnO or NSP-ZnO solutions with different concentrations (100, 200, 300, 500, 1000ppm). Take 5 mL of each solution into a test tube. After shaking to form a uniform white suspension, let it stand and observe the appearance of white precipitate at the bottom. , and record its time.

Example 2. Toxicity test of silicon wafer-zinc oxide composite to skin cells

Three skin cell lines (human epidermal cell HaCaT, human dermal fibroblast Hs68, mouse melanocyte B16F10) were each inoculated into each well of a 96well culture plate at a concentration of 2×10 ⁵ cells/mL, and cultured at 37°C. Incubate overnight in the box to allow adhesion. Add silicon wafer-zinc oxide complex solutions of different concentrations (0, 1, 10, 100, 500, 1000, 5000 ppm) and co-culture with the cells for 24 hours. Afterwards, the culture medium was removed, and 100 μL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazole bromide) solution (1 mg/mL) was added to each well. incubate for 2 hours, after which the MTT solution is removed. Add DMSO to each well, and measure the absorbance value at a wavelength of 595 nm. The results shown in Figures 3A-3C show that after 24 hours of interaction with the silicon wafer-zinc oxide complex solution of the present invention, the cell survival rate of human epidermal forming cells HaCaT at a concentration of 10 ppm was 51.78%, and the cell survival rate at a concentration of 100 ppm was 51.78%. The cell survival rate of human skin fibroblast Hs6 was 68.57% at a concentration of 1 ppm, and the cell survival rate was 14.47% at a concentration of 10 ppm (Fig. 3B); the survival rate of mouse skin melanoma cells at a concentration of 1 ppm The cell survival rate was 88.39%, and the cell survival rate at a concentration of 10 ppm was 38.68% (Fig. 3C). Based on this, it was deduced that the silicon wafer-zinc oxide complex of the present invention has an effect on epidermal forming cells HaCaT, human skin fibroblasts and melanocytes. The IC50 doses of B16F10 are 14.39ppm, 3.12ppm and 7.16ppm respectively.

In addition, according to the OECD TG 439 Skin Irritation Test guidelines, the skin and eye irritation test of the silicon wafer-zinc oxide complex was conducted. The results showed that the silicon wafer-zinc oxide complex was mixed with A 20% aqueous solution of pure water, non-irritating to skin and eyes (NI, Non-irritant).

ZnO/NSP percutaneous absorption/microscopic examination

3D Skin transdermal absorption experiment of ZnO/NSP (16%)

This experiment uses human recombinant epidermal tissue MatTek, EPI-200-SIT (surface area: 0.6cm ² ) as the source of 3D skin material, and conducts a percutaneous absorption test of NSP-ZnO suspension (experimental sample) with a concentration of 16%. The subcutaneous fluid (DMEM medium) without 16% experimental sample was the control group. Place 0.05mL of 16% sample on the 3D skin, and place 1.0mL of culture medium (DMEM medium) under the skin. After 6 and 24 hours of transdermal absorption, aspirate the sample on the 3D skin and slightly rinse the surface with culture solution. Collect subcutaneous culture fluid and 3D skin and refrigerate. The subcutaneous culture fluid and 3D skin collected from each experimental group were sent to SGS to detect the content of silicon and zinc. The detection method was ICP/OES, and the detection limits were: Si: 10ppm, Zn: 1.0ppm.

It is known that the concentration of NSP-ZnO Hybrid suspension on skin tissue is 16%, which is 160,000ppm; assuming NSP: ZnO (weight ratio) = 44.8: 55.2, the data in the table below can be calculated. The data in Table 2 below shows that a very small amount of NSP-ZnO entered the subsurface tissue during the experiment, and the rate of passing through the skin was extremely low.

3D Skin percutaneous absorption of ZnO/NSP (16%) (microscopic examination)

The percutaneous absorption of NSP-ZnO particles was further examined under a microscope. After 6 and 24 hours of transdermal absorption experiments as described above, the excess samples on the human epidermal tissue were aspirated, and then slightly rinsed with DMEM culture medium. Afterwards, the epidermal tissue was embedded in paraffin, stained with H&E and sectioned. Observe the upper layer of epidermal tissue using a light microscope.

The results shown in Figures 4A-4B show that regardless of the 6-hour experimental group or the 24-hour experimental group, residual particles of NSP-ZnO were found outside the stratum corneum of the skin. The stratum corneum of the 24-hour group appeared looser, and the outermost stratum corneum was partially peeled off. However, no obvious NSP-ZnO particles were observed inside the stratum corneum or in the granular layer cells. It was shown that the amount of NSP-ZnO particles entering the epidermal tissue during the experiment was very low and almost invisible.

Example 3. Skin protection efficacy test of silicon wafer-zinc oxide complex

UV absorbing ability

It can be clearly seen from the comparison results of the full spectrum scan (200~600nm) in Figure 5 that the silicon wafer-zinc oxide composite of the present invention exhibits stronger UV absorption ability. The maximum absorption of NSP-ZnO is at 367nm, which is shifted to the left compared with commercially available ZnO (maximum absorption at 375nm). This is related to the size of ZnO particles. When the size of the particles is smaller, it needs to express surface plasmon resonance (SPR). ) the required frequency increases, so the absorption wavelength will decrease. It is shown that the zinc oxide particles attached to the silicon wafer-zinc oxide composite of the present invention have significantly smaller particles than commercially available ZnO particles, and have relatively better ultraviolet absorption capabilities.

Extinction coefficient analysis

Molar extinction coefficient, also known as molar absorptivity, is a measure of how strongly a chemical absorbs light at a specific wavelength. It is an inherent property of the species; according to Beer-Lambert law, the formula is A=ε cl, where A=absorbance value, c=concentration, l=cell length, and the unit of ε is usually M-1cm ^-1 or L mol-1cm ^-1 . Another measure of extinction coefficient is E1,1 (mass extinction coefficient). E _1,1 is the absorbance of 1% solution in g-1L cm-1. ε and E _1,1 can be converted using the following equation: ε = (E _1,1 *molecular weight)/10.

Experimental method: First, prepare a suspension of 1.0 mg/mL ZnO/NSP complex and commercially available zinc oxide. Use Spectrophotometer to perform full spectrum scanning of UV/visible light (200~600nm) and calculation of extinction coefficient. The maximum absorbance of ZnO/NSP Hybrid at 1.0mg/mL is 367nm; the maximum absorbance of commercially available ZnO at 1.0mg/mL is 375nm.

The higher the extinction coefficient, the better its light-shielding ability. From the above results, it can be concluded that no matter which formula is used to calculate, the silicon wafer-zinc oxide composite (ZnO/NSP) of the present invention has a higher extinction coefficient than commercially available ZnO. If E1,1 (mass extinction coefficient) is considered, after 100% ZnO is modified into a ZnO/NSP composite, its extinction coefficient increases by approximately 37%. This result may also come from the adsorption of the present invention on the silicon wafer. Zinc oxide has smaller particle size and better dispersion effect. Based on the above results, the silicon wafer-zinc oxide composite (ZnO/NSP) of the present invention can provide better UV protection effect on the skin than commercially available ZnO.

Antibacterial effect

The silicon chip-zinc oxide composite of the present invention was tested against five pathogenic bacteria ( Aspergillus brasiliensis , ATCC 16404), Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 8739), white Antibacterial effect of Candida albicans (ATCC 10231) and Pseudomonas aeruginosa (ATCC 9027). The bacterial suspension without sample was used as the negative control group (not expected to have antibacterial effect); bacteria containing antibiotics The seed suspension is the positive control group (expected to have antibacterial effect); the blank control group is the culture medium without the strain suspension. The inoculation amount of each group is 10 ⁵ ~ 10 ⁶ cfu/mL of bacterial liquid. After inoculation, Cultivation in the optimal growth environment for each strain (aerobic bacteria: 35°C ± 2.0°C; yeast: 32°C ± 2.0°C; mold: 25°C ± 2.0°C), shaking at 200 rpm for 18 to 72 hours. The culture is completed After that, take out the culture medium, inoculate it on the medium containing the NSP-ZnO Hybrid sample prepared with the culture medium to the concentration required for the experiment, and culture it under the optimal growth conditions of each bacterial species (aerobic bacteria: 35℃±2.0℃; 24 hours; yeast: 32℃±2.0℃; 48 hours; mold: 25℃±2.0℃; 72~96 hours), observe the growth status and record the minimum inhibitory concentration.

In order to confirm that the improvement in antibacterial efficacy comes from the silicon wafer-zinc oxide complex of the present invention, the effects of silicon wafer (NSP), zinc oxide (ZnO) and silicon wafer-zinc oxide complex (ZnO/NSP) were further compared. Antibacterial activity of E.coli . Incubate silicon flakes, zinc oxide and silicon flake-zinc oxide complex solutions with concentrations of 0, 50, 70, 100, 200 and 500ppm with E. coli (1x10 ⁶ CFU/mL) for 8 hours (37°C, 200rpm). Then measure the OD600 value of each culture solution. The results are listed in Table 5 below.

The results show that pure silicon flakes (NSP) do not have antibacterial activity at a concentration lower than 500ppm; zinc oxide (ZnO) only shows antibacterial activity at a concentration of 200ppm; and the silicon flake-zinc oxide composite of the present invention The compound (ZnO/NSP) has antibacterial activity at a concentration of 70ppm, indicating that the zinc oxide attached to the silicon wafer can indeed enhance its antibacterial effect.

Test of the inhibitory concentration of silicon wafer-zinc oxide complex against Bacillus dandruff

The testing method is based on the method described in Andrews JM., J Antimicrobio Chemother 48 suppl 1:5-16, 2001. Malassezia globosa (BCRC 23114) was cultured at 30℃±2℃ in an aerobic environment for 5 days. The bacterial quantity is adjusted to the desired bacterial count of 1.5 x10 ⁸ CFU/mL. The experimental group and the control group were individually added with bacterial solution with an inoculation amount of 1%, and the final bacterial amount added was 10 ⁴ ~ 10 ⁵ CFU/mL. Serially dilute the bacterial suspension culture medium without samples (control group, pH 5.40 at 25°C), and observe and record the growth status after cultivation. The experimental groups are: FS21092401S4 (prepared from NSP-ZnO compound powder with culture medium to 0.1% liquid, pH 5.86 at 25°C); and FS21092402S4 (prepared from NSP-ZnO compound liquid with culture medium to 1% liquid , pH 6.18 at 25℃). After vaccination, the control group and the experimental group were treated respectively under the action conditions (30℃±2℃; aerobic environment; 48 hours of action). Serial dilutions were performed at 24 hours and 48 hours, and the growth status was observed and recorded after culture. The results are shown in Table 6 below.

Calculation formula of bacterial reduction rate (%):

In addition, the results in Figure 6 show that the silicon wafer-zinc oxide composite (ZnO/NSP) of the present invention, whether it is prepared as powder or liquid, can observe the growth of Malassezia spherica at a concentration of 1000 ppm. Growth is completely inhibited.

Example 4. Preparation Example of Cosmetic Composition of Silicon Chip-Zinc Oxide Complex

sunscreen lotion

The following table lists a formula example of a sunscreen emulsion composition (W/O emulsion). According to the conventional emulsion production process, the silicon wafer-zinc oxide composite (ZnO/NSP) of the present invention is first introduced into the water phase to prepare a W/O emulsion.

The following table lists a formula example of a sunscreen emulsion composition (W/O emulsion). According to the conventional emulsion production process, the silicon wafer-zinc oxide composite (ZnO/NSP) of the present invention is first introduced into the oil phase to prepare a W/O emulsion.

In addition, commercially available ZnO (which is lipophilic) was used to prepare a W/O emulsion by entering the oil phase first. Each emulsion obtained was tested for sun protection. SPF (Sun Protection Factor), UVAP and Star Rating are UVB and UVA protection effectiveness indicators respectively. In this example, UVA (320-400nm) and UVB (290-320nm) are used to irradiate the PMMA substrate coated with the test emulsion. After integration The ball collects the light after penetration, checks the transmittance of each test emulsion every 1nm in the 290-400nm range, and converts it with the UV-2600 SPF Calculator software to obtain the SPF value, UVAP and Star Rating. Table 7 below shows the test results.

The emulsion made of the silicon wafer-zinc oxide composite in the present invention is hydrophilic and is first dispersed in the water phase. Compared with commercially available zinc oxide, the emulsion is first dispersed in the oil phase and is lipophilic. Micro grade silicon flake-zinc oxide composite powder is easy to disperse and operate in water, and is not easy to aggregate. The emulsion made by it will not produce a white feeling when applied to the skin. It has a non-greasy and refreshing feeling, and is easy to apply makeup on the face or clean the body.

Anti-dandruff shampoo

The following table lists a formula example of an anti-dandruff shampoo adding 1% of the silicon flake-zinc oxide complex liquid of the present invention.

According to the conventional shampoo production process, the silicon flake-zinc oxide composite (ZnO/NSP) of the present invention is added to the conventional shampoo formula with a liquid ZnO content of 4.2% to prepare a formula containing A shampoo product equivalent to 420ppm ZnO (YH-040 shampoo). In addition, a shampoo product (YH-040-1 shampoo) with a content of 2% added liquid ZnO was prepared.

Combining the test results of the above-mentioned Examples 2 and 3, the silicon chip-zinc oxide composite of the present invention has the effect of inhibiting Bacillus dandruff. Compared with commercially available Zinc Pyrithione (ZPT, which has been banned by the European Union since March 2022), the ZnO-NSP of the present invention is non-toxic and suitable for daily use. It can provide necessary nutrients for hair growth and inhibit the growth of scalp microorganisms. , maintain a healthy scalp environment.

Based on the above, the silicon wafer-zinc oxide composite of the present invention is hydrophilic, and its powder is easy to disperse and handle in water, and will not aggregate. The finished product will not produce irritation or a white feeling that makes consumers uncomfortable when applied to the skin, and it will also feel non-greasy and refreshing. In particular, the present invention uses silicon flakes as the carrier of zinc oxide particles, which can make the zinc oxide particles more evenly dispersed and adsorbed on the silicon flakes, thereby improving its ultraviolet absorption capacity and antibacterial effect. It can not only effectively reduce the usage of zinc oxide, It has also been proven by experiments that it is not toxic to skin cells, and the amount of penetration into the internal tissues of the skin is extremely low. It can be safely used in skin protection compositions, especially cosmetic compositions applied to human skin.

Claims (9)

A use of a silicon flake-on-silicate platelet composite (ZnO-on-silicate platelet composite) for preparing a skin protection composition, wherein the silicon flake-zinc oxide composite is made by adding an aqueous solution of zinc salt to a silicon flake suspension It is made by carrying out a metal ion exchange reaction, using NaOH to form zinc hydroxide on the surface of the silicon wafer, and then dehydrating it to form zinc oxide particles and adsorbing them on the surface of the silicon wafer. The use as claimed in claim 1, wherein the composition is a cosmetic composition. The use as claimed in claim 1, wherein the composition is used to protect skin from bacterial infection. A cosmetic composition for protecting skin, comprising a 5%-25% silicon flake-zinc oxide complex and a carrier, excipient or diluent, wherein the silicon flake-zinc oxide complex is prepared by adding zinc The aqueous salt solution is added to the silicon wafer suspension to perform a metal ion exchange reaction, and NaOH is used to form zinc hydroxide on the surface of the silicon wafer, which is then dehydrated to form zinc oxide particles and adsorbed on the surface of the silicon wafer. The cosmetic composition of claim 4, wherein the cosmetic composition is a skin protective cream or lotion. The cosmetic composition according to claim 5, wherein the cosmetic composition is a sunscreen lotion. The cosmetic composition according to claim 4, wherein the cosmetic composition is a skin care cleansing product. The cosmetic composition as claimed in claim 7, wherein the cosmetic composition is a shampoo/milk. The cosmetic composition according to claim 4, wherein the cosmetic composition is a hair tonic.

Images